China translation fail

THE US Food and Drug Administration (FDA) has released a warning letter sent last Monday to China-based Guangdong Zhanjiang Jimin Pharmaceutical Co. after finding that one of the over-thecounter drugs the firm made was labeled as containing the active pharmaceutical ingredient (API) hydrocortisone, but really the drug contained dexamethasone acetate.

The company told FDA that the mix-up is the result of “a translation mistake,” according to the warning letter.

The FDA said it found other product anomalies that did not meet standards.

MEANWHILE China Food and Drug Administration has moved to strengthen oversight of online sales of drugs and medical devices, according to the Regulatory Affairs Professionals Society.